BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38302151)

  • 1. The Current and Future Roles of Precision Oncology in Advanced Breast Cancer.
    Jacene H; Dietsche E; Specht J
    J Nucl Med; 2024 Mar; 65(3):349-356. PubMed ID: 38302151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Imaging and Precision Medicine in Breast Cancer.
    Chudgar AV; Mankoff DA
    PET Clin; 2017 Jan; 12(1):39-51. PubMed ID: 27863565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
    Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
    Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
    Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
    Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Breast Cancer Imaging in the Era of Precision Medicine.
    Muzahir S
    AJR Am J Roentgenol; 2020 Dec; 215(6):1512-1519. PubMed ID: 33084364
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel applications of molecular imaging to guide breast cancer therapy.
    Edmonds CE; O'Brien SR; Mankoff DA; Pantel AR
    Cancer Imaging; 2022 Jun; 22(1):31. PubMed ID: 35729608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized & Precision Medicine in Cancer: A Theranostic Approach.
    Choudhury P; Gupta M
    Curr Radiopharm; 2017 Nov; 10(3):166-170. PubMed ID: 28758574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
    He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
    PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.
    Basu S; Alavi A
    PET Clin; 2016 Jul; 11(3):203-7. PubMed ID: 27321025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of non-FDG-PET in the management of head and neck cancer.
    Heuveling DA; de Bree R; van Dongen GA
    Oral Oncol; 2011 Jan; 47(1):2-7. PubMed ID: 21109481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
    Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
    J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
    Bottoni G; Piccardo A; Fiz F; Siri G; Matteucci F; Rocca A; Nanni O; Monti M; Brain E; Alberini JL; Dib B; Sacchetti GM; Saggia C; Rossi V; Harbeck N; Wuerstlein R; Degenhardt T; DeCensi A; Rollandi GA; Gennari A
    Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision Medicine and PET/Computed Tomography in Melanoma.
    Mena E; Sanli Y; Marcus C; Subramaniam RM
    PET Clin; 2017 Oct; 12(4):449-458. PubMed ID: 28867115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
    Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
    Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma.
    Gilardi L; Airò Farulla LS; Curigliano G; Corso G; Leonardi MC; Ceci F
    Biomedicines; 2023 May; 11(5):. PubMed ID: 37239021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing anti-body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology.
    Subbiah V
    Curr Probl Cancer; 2021 Oct; 45(5):100799. PubMed ID: 34706831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry.
    Le Tourneau C; Perret C; Hackshaw A; Blay JY; Nabholz C; Geissler J; Do T; von Meyenn M; Dienstmann R
    JCO Precis Oncol; 2022 Jul; 6():e2200019. PubMed ID: 35939770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.